Trevena, Inc. Announces Closing Of Initial Public Offering

Published: Feb 06, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the closing of its initial public offering of 9,250,000 shares of common stock at an initial public offering price of $7.00 per share.

Help employers find you! Check out all the jobs and post your resume.

Back to news